C16

PKR kinase inhibitor

Product Specifications

Background

C16 is a derivative of imidazolo-oxindole and inhibits RNA-dependent protein kinases (PKR). Its inhibition effect on PKR is ATP-binding site directed. C16 has been shown to specifically inhibit the apoptotic PKR/eIF2a signaling pathway.

CAS Number

608512-97-6

Product Name Alternative

Imidazolo-oxindole PKR inhibitor C16, 6,8-Dihydro-8- (1H-imidazol-5-ylmethylene) -7H-pyrrolo[2,3-g]benzothiazol-7-one

UNSPSC

41116105

Type

Inhibitor

Source

Synthetic

Field of Research

Cell Signaling | Cancer | Apoptosis | Cancer Growth Inhibitors | Tyrosine Kinase Inhibitors

Purity

≥98% (HPLC)

Weight

0.025

Format

Solid

Solubility

Soluble in DMSO 12 mg/ml

Molecular Formula

C13H8N4OS

Molecular Weight

268.3

Precautions

Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only.

References & Citations

1. Couturier J., et al. (2010) J. Biol. Chem. 285(2): 1272–1282. 2. Jammi N.V., Whitby L.R., & Beal P.A. (2003) Biochem. Biophys.Res. Comm. 308(1):50–57.